Glycopyrronium Martindale

Glycopyrronium Martindale is a product containing active ingredient glycopyrronium bromide. It is supplied as an injectable solution for intramuscular and intravenous use. Marketed in the European Union and available by prescription only, this anticholinergic (muscarinic antagonist) belongs to the antimuscarinic agent class and carries ATC code R03BB04. It works by competitively blocking muscarinic acetylcholine receptors to reduce parasympathetic activity. It is employed in patients requiring airway management during surgery.

Glycopyrronium Martindale is administered in clinical settings where reduction of muscarinic activity is desired.

- As an adjunct to anesthesia to decrease oral, respiratory, and gastric secretions. - To manage excessive sweating (hyperhidrosis) in refractory cases. - For treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) when other therapies are insufficient. - To facilitate endotracheal intubation by reducing airway secretions. - In certain cardiac surgeries to control vagal tone.

Side effects of Glycopyrronium Martindale reflect its anticholinergic activity and vary in frequency.

Common: - Dry mouth. - Reduced sweating. - Blurred vision. - Constipation. - Urinary retention.

Serious: - Tachycardia. - Severe hypotension. - Acute angle‑closure glaucoma. - Allergic reactions such as rash or anaphylaxis. - Cardiac arrhythmias.

Before using Glycopyrronium Martindale, clinicians should consider several precautionary factors to ensure safe administration.

- Assess for known hypersensitivity to glycopyrronium or similar anticholinergics. - Use caution in patients with glaucoma, especially narrow‑angle type. - Monitor cardiac function in individuals with pre‑existing arrhythmias or coronary disease. - Evaluate renal or hepatic impairment as drug elimination may be altered. - Avoid in patients with severe urinary retention or gastrointestinal obstruction. - Consider dose adjustment in the elderly.

Glycopyrronium Martindale can interact with other medications that influence cholinergic pathways or cardiovascular function.

Avoid: - Other anticholinergic agents (e.g., atropine, scopolamine) due to additive effects. - Sympathomimetic drugs that may exacerbate tachycardia. - Monoamine oxidase inhibitors when combined with certain bronchodilators.

Use with caution: - Beta‑agonist bronchodilators (e.g., albuterol) as combined effect on airway tone may occur. - Drugs that prolong the QT interval. - Anesthetic agents that depress cardiac output.